By Qure.aiLearning Objectives
- Understand what Qure.ai does across chest X-ray, head-CT, and lung-nodule imaging
- Identify its dual role in Western hospitals and global-health screening
- Evaluate the strengths and limits of detection-and-triage radiology AI
What Is Qure.ai?
Qure.ai is a medical-imaging AI company whose deep-learning tools read radiology exams and flag likely abnormalities. Its best-known products are qXR for chest X-rays, qER for head CT scans, and qCT for lung nodules. The software analyzes an image, highlights suspected findings, and prioritizes urgent cases on the radiologist's worklist — and in places with too few radiologists, it extends diagnostic reach where expert reads are scarce. Founded in 2016 with operations across Mumbai, New York, and London, Qure.ai is one of the most globally deployed radiology-AI vendors, reporting use in more than 100 countries.
Qure.ai has built an unusually broad regulatory portfolio: by early 2026 it reported 26 FDA indications across nine products, including a February 2026 batch of six new chest X-ray clearances. What makes the company distinctive is its dual identity. It sells into high-tech Western hospital systems for triage and workflow acceleration, and it also powers large-scale global-health screening programs — tuberculosis and lung-cancer detection across Africa, Asia, and Latin America — where an AI read can stand in for a radiologist who simply is not available. That reach is its differentiator against narrower, single-market imaging vendors.
💡Key Concept
Detection and triage: Qure.ai's tools do two related jobs — detect a likely finding on an image, and triage the worklist so urgent cases (a large bleed on head CT, a suspicious lung nodule) are seen first. Both accelerate the human radiologist rather than replacing the final read.
⚠️Warning
Clearances are indication-specific. A regulatory clearance covers a defined finding, imaging type, and population — it does not mean the tool reads everything. Performance also depends on image quality and the patient population, and the radiologist remains responsible for the final interpretation.
✅Tip
Visit Qure.ai: qure.ai — enterprise and program-based deployment.
Pricing
Qure.ai sells through enterprise and program agreements rather than public list pricing — hospital deployments are typically priced by volume or subscription, while global-health programs are funded through public-health and partner arrangements.
- Chest X-ray, head-CT, and nodule tools
- Worklist triage integration
- Volume or subscription pricing
- Tuberculosis and lung-cancer screening
- High-volume, resource-limited settings
- Partner and public-health funding
Core Features
Chest X-Ray Analysis (qXR)
Detects and flags a wide range of chest X-ray findings and triages abnormal studies — the product area where Qure.ai reports the deepest regulatory portfolio.
Head-CT Triage (qER)
Analyzes non-contrast head CT for critical findings such as intracranial bleeds, prioritizing them on the worklist so urgent cases are read first.
Lung-Nodule Detection (qCT)
Identifies and characterizes lung nodules on CT, supporting lung-cancer screening and follow-up workflows.
Global-Health Screening
Powers large tuberculosis and lung-cancer screening programs in resource-limited settings, where an AI read extends access to expertise that would otherwise be unavailable.
Strengths
- Broad regulatory portfolio — 26 FDA indications across nine products as of early 2026
- Global scale — deployed in more than 100 countries
- Dual market — high-tech hospital triage plus global-health screening
- Worklist prioritization — surfaces urgent findings faster
- Extends access — brings a first read where radiologists are scarce
Limitations and Considerations
- Indication-specific clearances — each covers a defined finding, not everything on the image
- Image-quality and population dependence — accuracy varies with input quality and setting
- Human-in-the-loop — accelerates but does not replace the radiologist's final read
- Integration effort — value depends on fitting cleanly into existing worklist and systems
- Evidence varies by product — maturity differs across the nine-product portfolio
Best Use Cases
| Use Case | Why Qure.ai Fits | Caveat |
|---|---|---|
| Emergency head-CT triage | qER prioritizes critical bleeds | Covers defined findings only |
| Chest X-ray workflow acceleration | Deep qXR portfolio and clearances | Radiologist confirms the read |
| Tuberculosis and lung screening programs | Extends reach in low-resource settings | Program design and quality control matter |
| Lung-nodule follow-up | qCT detects and characterizes nodules | Part of a broader screening pathway |
Key Takeaways
- Qure.ai is a globally deployed radiology AI for chest X-ray (qXR), head CT (qER), and lung nodules (qCT), detecting findings and triaging worklists
- It reported 26 FDA indications across nine products by early 2026 and use in more than 100 countries
- Its distinctive dual identity spans Western hospital triage and large global-health screening programs for tuberculosis and lung cancer
- Clearances are indication-specific and performance depends on image quality and population; the radiologist owns the final read
- It is best for accelerating urgent-finding triage and extending diagnostic reach where expert reads are scarce
